Aurobindo Gets USFDA Nod to Manufacture Ibuprofen Capsules
Aurobindo Pharma Ltd. received final approval from the US Food & Drug Administration (USFDA) to manufacture Ibuprofen capsules. The Hyderabad based company’s Ibuprofen capsules are the generic equivalent of Pfizer’s Advil Liqui-Gels capsules. The product will be launched in September 2018. Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, muscular aches, and minor pain of arthritis. It is also used to reduce fever and to relieve from minor aches and pain due to common cold or flu. The estimated market size of Ibuprofen capsules OTC is $164-mn for the 12 months ended March 2018, according to Nielsen data. This is the 143rd ANDA (including 19 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, used for manufacturing oral products.
You May Interested In
2026-07-26
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
In 2021, India's Ibuprofen API Export Volume and Price will Fall
-
NTU has developed a new method for synthesizing anti-inflammatory drugs
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
Jinggong Tech H1 Net Profit Soars 15 Percent Revenue Reaches 1.06 Billion Yuan Carbon Fiber Equipment Drives 59 Percent of Sales
-
关于加强防范钓鱼邮件的通知 Notification on Strengthening Anti-Phishing Measures
-
关于全面排查下架易制毒及易制爆产品信息的公告 Announcement on the Comprehensive Review and Removal of Product Information Related to Precursor and Explosive Precursor Chemicals
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
The FDA Officially Blesses AI for Liver Drug Development
-
U.S. FDA Opens New Safety Review of RSV Treatments for Infants
-
WACKER Launches Next-Gen Polysilicon Line in Germany 50 Percent Capacity Boost Targets Semiconductor Demand
Recommend Reading
-
Torrent Pharma Targets First Wave Semaglutide Launch Revenue Up 11 Percent as Patent Ends
-
A Fake Email Drains RMB 12 Million: Asia’s Waterproof Giant’s Overseas ‘Payment Heist’ Exposes the Fatal Blind Spot of Chinese Corporate Globalization
-
Yangon Cuts Palm Oil Purchase Limit to 4.1kg per Order New Policy Effective August 4
-
U.S. Delays Mandatory GRAS Notification Proposal, Pushing Food-Additive Overhaul to Year-End
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
Tert Butylate: Properties and Applications
-
Cost Side Rebounds, Polyester Staple Fiber Prices Rise Slightly
-
High Supply Remains Firm, Weakness in ABS Market Persists at End of October in China
-
Supply and Demand Bearish, Toluene Market Declines
-
Weak Demand Weighs on Butadiene Market